Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 5/20 | 0.48 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6029993 | 0.89 | MEN1 (0.58) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| Hydrochloric Acid SCHEMBL14487414 | 0.88 | MEN1 (0.56) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL1466529 | 0.86 | NR4A2 (0.65) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL462496 | 0.86 | NPSR1 (0.47) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL6030723 | 0.82 | KDM4E (0.55) | KMT2AALDH1A1HPGDNR4A2 | |
| SCHEMBL2535362 | 0.82 | ALDH1A1 (0.51) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL16619064 | 0.81 | PBRM1 (0.54) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL1465827 | 0.81 | ALDH1A1 (0.68) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL24143313 | 0.80 | MEN1 (0.52) | MEN1KMT2AALDH1A1CYP1A2HPGD | |
| SCHEMBL6030284 | 0.80 | NR4A2 (0.73) | ALDH1A1NR4A2LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034668-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10370358-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-20180194746-A1 | Compounds For the Treatment of HIV | GILEAD SCIENCES, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9944619-B2 | Compounds for the treatment of HIV | GILEAD SCIENCES, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| EP-2729448-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2013006738-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES, INC. (US) | 2013-01-10 | — | — | WO | disclosed |
| US-7109229-B2 | Methods and compounds for treating proliferative diseases | ELI LILLY AND COMPANY (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1325011-B1 | METHODS AND COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | LILLY CO ELI (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | ENGLER THOMAS ALBERT (US) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10370358-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
| US-20180194746-A1 | Compounds For the Treatment of HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
| US-20040048915-A1 | Methods and compounds for treating proliferative diseases | CDK4, CCNI, CCNA1 | MEN1 2055/4885KMT2A 1627/4885ALDH1A1 450/4885 |
| US-11034668-B2 | Compounds for the treatment of HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
| US-20140142085-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
| US-20230012449-A1 | COMPOUNDS FOR THE TREATMENT OF HIV | CCR5, NPC1, FURIN | MEN1 2645/4885KMT2A 2804/4885ALDH1A1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.